Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management-authors' response

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 5, 2011, Pages 1198-1199

  Parkins, M D ^a,b,c   Elborn, J S ^c,d  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c BELFAST CITY HOSPITAL   (United Kingdom)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Pharmacokinetics; Pneumonia; Tigecycline

Indexed keywords

TIGECYCLINE;

ACHROMOBACTER XYLOSOXIDANS; AREA UNDER THE CURVE; COMMUNITY ACQUIRED PNEUMONIA; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; MORTALITY; NONHUMAN; PHYSICIAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 79954582458     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr036     Document Type: Letter

References (10)

1. Cooreman S, Jeurissen A. Comment on: Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management. J Antimicrob Chemother 2011; 66: 1195-6.
2. Parkins MD, Elborn JS. Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management. J Antimicrob Chemother 2010; 65: 1853-61.
3. Hansen CR, Pressler T, Hoiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008; 7: 523-30.
4. Lebecque P, Leal T, Zylberberg K et al. Towards zero prevalence of chronic Pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros 2006; 5: 237-44.
5. FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm (24 January 2011, date last accessed).
6. St Denis M, Ramotar K, Vandemheen K et al. Infection with Burkholderia cepacia complex bacteria and pulmonary exacerbations of cystic fibrosis. Chest 2007; 131: 1188-96.
7. Aaron SD, Ramotar K, Ferris W et al. Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med 2004; 169: 811-5.
8. Chaubey V, Dalton BR, Sabuda D et al. Ceftobiprole use in methicillin resistant Staphylococcus aureus (MRSA) bacteremia and pneumonia. Association of Medical Microbiology and Infectious Disease of Canada, Edmonton, Alberta, 2010. Abstract SP26.
9. Freire AT, Melnyk V, Kim MJ et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010; 68: 140-51.
10. Lechtzin N, John M, Irizarry R et al. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration 2006; 73: 27-33.